COMP <GO>
PCVX vs RGEN // REVENUE GROWTH (YOY)
Vaxcyte Inc. (NASDAQ) VS. Repligen Corporation (NASDAQ) • 15-METRIC TALLY: PCVX 3
— RGEN 7
▲ REVENUE GROWTH (YOY) LEADER: PCVX
LAST: $60.62 (-2.27%) • MKT CAP: $9.54B
revenue-growth
19.80%
LAST: $172.95 (-2.25%) • MKT CAP: $11.06B
revenue-growth
-3.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. RGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | RGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | 2.30% | -29.90 | RGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 95.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | 0.88% | -7.67 | RGEN | /fcf-yield <GO> |
| Operating Margin | -33.50% | 1.80% | -35.30 | RGEN | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 1.60% | -1.60 | RGEN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 19.80% | -3.30% | +23.10 | PCVX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 9.31 | +8.80 | PCVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 45.4 | -0.10 | RGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.04 | +0.03 | PCVX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.54B | $11.06B | -$1.51B | RGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | RGEN REV | PCVX GROSS % | RGEN GROSS % | PCVX FCF | RGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.59B | $154.5M | — | — | -$669.3M | $93.9M |
| FY 2024 | $1.59B | $98.3M | — | — | -$475.1M | $149.7M |
| FY 2023 | $1.31B | $133.6M | — | — | -$296.8M | $113.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
RGEN // BETA 1.04